Amgen's SWOT analysis: biotech giant's stock faces obesity market challenge#Amgen039s #SWOT #analysis #biotech #giant039s #stock #faces…
Tag: Obesity
Novo Nordisk CEO Exits Amid Obesity Drug Pressure
Novo Nordisk announced Friday that CEO Lars Fruergaard Jørgensen will step down, ending an eight-year tenure…
Novo Nordisk cuts 2025 outlook as Wegovy obesity drug sales slow
Novo Nordisk cuts 2025 outlook as Wegovy obesity drug sales slow#Novo #Nordisk #cuts #outlook #Wegovy #obesity…
Wall Street Lunch: Obesity Pill Progress
Wall Street Lunch: Obesity Pill Progress #Wall #Street #Lunch #Obesity #Pill #Progress
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients…
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) #Lexicon039s #Drug #Discovery…
Rhythm Pharmaceuticals regains rights to obesity drug in China
Rhythm Pharmaceuticals regains rights to obesity drug in China#Rhythm #Pharmaceuticals #regains #rights #obesity #drug #China
Roche recruits Novo executive for obesity drug market entry – Bloomberg
Roche recruits Novo executive for obesity drug market entry – Bloomberg#Roche #recruits #Novo #executive #obesity #drug…
Gubra soars 23% on on AbbVie obesity drug licensing deal
Gubra soars 23% on on AbbVie obesity drug licensing deal#Gubra #soars #AbbVie #obesity #drug #licensing #deal
Obesity drug outlook: Hopes for stronger treatments, adherence remains a hurdle
Obesity drug outlook: Hopes for stronger treatments, adherence remains a hurdle#Obesity #drug #outlook #Hopes #stronger #treatments…
Scholar Rock: More Than Just SMA Biotech With Q2 2025 Obesity Treatment Data (NASDAQ:SRRK)
This article was written by Follow Terry Chrisomalis is a private investor in the Biotech sector…
Metsera Readies $275 Million IPO For Obesity Treatments
Metsera Readies $275 Million IPO For Obesity Treatments #Metsera #Readies #Million #IPO #Obesity #Treatments